nctId: NCT06265051 id: 100939 briefTitle: Tirofiban After Successful MT Recanalization in AIS acronym: ATTRACTION overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2027-03-01 date: 2027-09-01 date: 2024-02-20 date: 2024-04-02 name: Xiang Luo class: OTHER name: Wuhan Central Hospital name: Wuhan University name: Renmin Hospital of Wuhan University name: Second Affiliated Hospital of Soochow University name: The First Affiliated Hospital of Zhengzhou University name: Wuhan Hospital of Traditional Chinese Medicine name: The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture name: Huangshi Central Hospital, China name: The First Affiliated Hospital of Yangtze University name: The Fifth Hospital of Wuhan name: Wuhan Puren Hospital name: Xiangyang No.1 People's Hospital name: Xianning Central Hospital name: Wuhan Hanyang Hospital name: Wuhan Third Hospital name: Yichang Central People's Hospital name: Affiliated Hospital of Chengde Medical University name: Beijing Tiantan Hospital name: Nanyang Central Hospital name: Jingzhou Central Hospital name: Taihe Hospital name: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School briefSummary: Acute ischemic stroke with large vessel occlusion is a frequently occurring life-threatening condition. Although endovascular treatment can effectively open occluded vessels, the successful reperfusion rate exceeds 80%, but the rate of good prognosis is less than 50%. The current clinical focus is on how to improve futile recanalization. Tirofiban is widely used in the treatment of stroke, as it can effectively prevent vascular reocclusion and improve microcirculation perfusion. It has the potential to improve futile recanalization, but there is a lack of high-level evidence-based medical support. This multicenter, prospective, double-blind, randomized controlled trial was conducted to assess the effectiveness and safety of sequential tirofiban therapy following successful mechanical thrombectomy within 24 hours of onset. conditions: Acute Ischemic Stroke conditions: Vessel Occlusion studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 1360 type: ESTIMATED name: Tirofiban name: Saline placebo measure: Proportion of patients functionally independent (mRS score 0 to 2) at 90 days measure: Number of participants with symptomatic intracranial hemorrhage measure: Modified ranking scale (mRS) measure: Proportion of patients non-disabled (mRS score 0 to 1) or return to pre-morbid mRS score at 90 days (for patients with mRS > 1) measure: Proportion of patients ambulatory or bodily needs-capable or better (mRS score 0 to 3) measure: Number of participants with improvement of neurological function measure: Health-related quality of life, assessed with the European Quality Five Dimensions Five Level scale (EQ-5D-5L) measure: All-cause mortality measure: Proportion of intracranial hemorrhage of any type sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False